Drug Investigation

, Volume 5, Issue 2, pp 93–97 | Cite as

A Review of Japanese Studies of Roxithromycin

Pharmacokinetics, Microbiology and Clinical Studies, Particularly in the Treatment of Respiratory Infection
  • Shigeru Kohno
  • Kohei Hara
  • Fumio Matsumoto
Review Article


The pharmacokinetic and microbiological data of roxithromycin, an oral semisynthetic macrolide, and its clinical use in respiratory infections in Japanese patients are reviewed. In healthy men the maximum plasma concentration (Cmax) and area under the plasma concentration-time curve (AUC) of roxithromycin increase with increasing dosage, as does urinary drug excretion. The drug’s Cmax and half-life are increased compared with erythromycin, josamycin and miocamycin. Maximum sputum and plasma drug concentrations were higher in patients with chronic bronchitis receiving roxithromycin 150mg than in those receiving erythromycin 400mg. Uptake of roxithromycin into polymorphonuclear cells was proportionally greater than that of erythromycin and josamycin. Roxithromycin showed good in vitro activity against respiratory pathogens, including intracellular pathogens such as Legionella pneumophila and Mycoplasma pneumoniae, although it had only about one-quarter of the activity of erythromycin against Staphylococcus aureus and Streptococcus pneumoniae. High success rates were obtained in patients with acute pneumonia (79%) and chronic obstructive airways disease (75%) receiving roxithromycin in a noncomparative trial in 378 patients with respiratory tract infection, and roxithromycin and miocamycin showed similar efficacy in a double-blind study.

Thus, roxithromycin concentrations achieved in sputum, plasma and intracellularly provide effective antimicrobial activity against respiratory pathogens, and this has been confirmed by the results of clinical trials.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Bergogne-Berezin E. Tissue distribution of roxithromycin. Journal of Antimicrobial Chemotherapy 20 (Suppl. B): 113–120, 1987PubMedCrossRefGoogle Scholar
  2. Bowie WR, Shaw CE, Chan DG, Black WA. In vitro activity of Ro 15-8074, Ro 19-5247, A56268 and roxithromycin (RU 28965) against Neisseria gonorrhoeae and Chlamydia trachomatis. Antimicrobial Agents and Chemotherapy 31: 470–472, 1987PubMedCrossRefGoogle Scholar
  3. Chantot JF, Bryskier A, Gase J-C. Antibacterial activity of roxithromycin: a laboratory evaluation. Journal of Antibiotics 39: 660–668, 1986PubMedCrossRefGoogle Scholar
  4. Hara K, Suyama N, Yamaguchi K, Kohno S, Saito A. Activity of macrolides against organisms responsible for respiratory infection with emphasis of Mycoplasma and Legionella. Journal of Antimicrobial Chemotherapy 20 (Suppl. B): 75–80, 1987PubMedCrossRefGoogle Scholar
  5. Hiraga H, Kikuchi K, Yamamoto A, et al. RU 28965 in respiratory infections. Chemotherapy 36 (Suppl. 4): 224–473, 1988Google Scholar
  6. Lapointe J-R, Lavallee C, Meilleur R, Bourget C. Roxithromycin alone and in combination with sulphamethoxazole against Haemophilus influenzae. Journal of Antimicrobial Chemotherapy 20 (Suppl. B): 21–29, 1987PubMedCrossRefGoogle Scholar
  7. Koyama M, Tateno M, Shirotsuka M, Yamamoto T, Hirayama M, et al. Absorption, metabolism and excretion of RU 28965 in humans. Chemotherapy 36 (Suppl. 4): 164–183, 1988Google Scholar
  8. Marsac JH. An international clinical trial on the efficacy and safety of roxithromycin in 40000 patients with acute community-acquired respiratory tract infections. Diagnostic Microbiology and Infectious Disease 15: 81S–84S, 1992PubMedCrossRefGoogle Scholar
  9. Masaki M, Inoue Y, Mashimoto H, Masuyama Y, Dohtsu Y, et al. Laboratory and clinical studies on RU 28965. Chemotherapy 36 (Suppl. 4): 421–437, 1988Google Scholar
  10. Nilsen OG, Aamano T, Zahlsen K, Svarva P. Macrolide pharmacokinetics and dose scheduling of roxithromycin. Diagnostic Microbiology and Infectious Disease 15: 71S–76S, 1992PubMedCrossRefGoogle Scholar
  11. Puri SK, Lassman HB. Roxithromycin: a pharmacokinetic review of a macrolide. Journal of Antimicrobial Chemotherapy 20 (Suppl.): 89–100, 1987PubMedCrossRefGoogle Scholar
  12. Ridgway GL. The in vitro activity of macrolides against Chlamydia trachomatis and the genital Mycoplasma. In Butzler & Kobayashi (Eds) Macrolides: a review and the outlook for future developments, pp. 57–60, University of Tokyo Press, Tokyo, 1986Google Scholar
  13. Saito A, Kato Y, Odagaki E, Shinohara M, Tomizawa M, et al. Pharmacokinetics and clinical results of RU 28965. Chemotherapy 36 (Suppl. 4): 216–223, 1988Google Scholar
  14. Shiba K, Saito A, Shimada J, Kaji M, Matsumoto F, et al. Basic and clinical studies on RU 28965. Chemotherapy 36 (Suppl. 4): 292, 1988Google Scholar
  15. Soejima R, Niki Y, Kishimoto T, Nakagawa Y, Sumi M, et al. Double-blind comparative study of roxithromycin (RU 28965) and midecamycin acetate (MOM) in the treatment of pneumonia. Journal of the Japanese Association for Infectious Diseases 63: 501, 1989PubMedGoogle Scholar
  16. Tilyard MW, Dovey SM. A randomized double-blind controlled trial of roxithromycin and cefaclor in the treatment of acute lower respiratory tract infections in general practice. Diagnostic Microbiology and Infectious Disease 15: 97S–101S, 1992PubMedCrossRefGoogle Scholar

Copyright information

© Adis International Limited 1993

Authors and Affiliations

  • Shigeru Kohno
    • 1
  • Kohei Hara
    • 1
  • Fumio Matsumoto
    • 2
  1. 1.Second Department of Internal MedicineNagasaki University School of MedicineNagasakiJapan
  2. 2.Department of Internal MedicineKanagawa Prefectural School of Nursing and Hygiene HospitalKanagawaJapan

Personalised recommendations